It was Abbvie who finished the half the stronger with three answered points including a brace from Brian Reape. Half Time Abbvie 1-05 1-04 Boston Scientific Scores were hard to come by in the ...

The primary endpoint of comprehensive disease control was defined as a combination of clinical remission (CDAI under 150; ...

Ironwood Pharmaceuticals, Inc.’s IRWD share price has surged by 5.57%, which has investors questioning if this is right time ...

SAN DIEGO -- Administering fecal microbiota via colonoscopy instead of rectally prevented recurrence of Clostridium difficile ...

Inflammation is likely a key player in atherosclerosis and related cardiovascular events, but questions remain about its role ...

Baron Health Care Fund retreated in the first quarter of 2025, underperforming its benchmark, the Russell 3000 Health Care ...

If consummated, the marriage will also give AbbVie access to Aliada's MODEL platform for delivering large-molecule drugs across the blood-brain barrier (BBB). The Boston biotech said the platform ...

President Donald Trump and his Cabinet spent the better part of their meeting touting the administration’s record on ...

Neoadjuvant PD-1 blockade in early-stage mismatch repair–deficient solid rectal and non-rectal tumors can eliminate the need ...

The deal is expected to give the US access to Ukraine’s valuable rare earth minerals while providing Kyiv a measure of ...